Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

Bone Marrow Transplantation

Volumn 23, Issue 12, 1999, Pages 1261-1266

  Rajkumar, S V ^a   Fonseca, R ^a   Lacy, M Q ^a   Witzig, T E ^a   Lust, J A ^a   Greipp, P R ^a   Therneau, T M ^a   Kyle, R A ^a   Litzow, M R ^a   Gertz, M A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Complete response; Multiple myeloma; Prognostic factors; Transplantation; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; AGED; ARTICLE; BONE MARROW; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SURVIVAL; BLOOD; BONE MARROW CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION;

ADULT; AGED; BETA 2-MICROGLOBULIN; BONE MARROW CELLS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; REMISSION INDUCTION;

EID: 0033516045     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701787     Document Type: Article

References (33)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-9.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
3. Bataille R, Harousseau JL. Multiple myeloma. New Engl J Med 1997; 336: 1657-1664.
4. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New Engl J Med 1994; 330: 484-489.
5. Kyle RA. Long-term survival in multiple myeloma. New Engl J Med 1983; 308: 314-316.
6. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997; 34 (Suppl. 1): 61-66.
7. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
8. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-793.
9. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
10. Barlogie B, Jagannath S, Epstein J et al. Biology and therapy of multiple myeloma in 1996. Semin Hematol 1997; 34 (Suppl. 1): 67-72.
11. Greipp PR, Lust JA, O'Fallon WM et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
12. Greipp PR, Witzig TE, Gonchoroff NJ. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am J Hematol 1985; 20: 289-292.
13. Witzig TE, Gonchoroff NJ, Katzmann JA et al. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. J Clin Oncol 1988; 6: 1041-1046.
14. ISCN (1995). Mitelman F. An International System for Human Cytogenetics Nomenclature. S. Karger: Basel, 1995.
15. Spurbeck JL, Carlson RO, Allen JE, Dewald GW. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet Cytogenet 1988; 32: 59-66.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-202.
18. Kovacsovics TJ, Delaly A. Intensive treatment strategies in multiple myeloma. Semin Hematol 1997; 34 (Suppl. 1): 49-60.
19. Oken MM, Harrington DP, Abramson N et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79: 1561-1567.
20. Katzmann JA, Greipp PR, O'Fallon WM, Kyle RA. Serum beta 2-microglobulin. Mayo Clin Proc 1986; 61: 752-753.
21. Tricot G, Sawyer JR, Jagannath S et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659-2666.
22. Garewal H, Dune BG, Kyle RA et al. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984; 2: 51-57.
23. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells 1995; 13 (Suppl. 2): 56-63.
24. Rajkumar SV, Fonseca R, Lacy MQ et al. Abnormal cytogenetics predict for poor survival after peripheral blood stem cell transplantation in relapsed multiple myeloma (abstract). Blood 1997; 90 (Suppl. 1): 527a.
25. Simpson DR, Berkahn LC, Squire J et al. Prognostic significance of cytogenetics in patients with multiple myeloma referred for autologous stem cell transplant (ABMT) (abstract). Blood 1997; 90 (Suppl. 1): 527a.
26. Alexanian R, Barlogie B, Ventura G. Chemotherapy for resistant and relapsing multiple myeloma. Eur J Haematol 1989; 51 (Suppl.): 140-144.
27. Gertz MA, Pineda AA, Chen MG et al. Refractory and relapsing multiple myeloma treated by blood stem cell transplantation. Am J Med Sci 1995; 309: 152-161.
28. Alexanian R, Dimopoulos MA, Delasalle KB et al. Myeloablative therapy for primary resistant multiple myeloma. Stem Cells 1995; 13 (Suppl. 2): 118-121.
29. Attal M, Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin N Am 1997; 11: 133-146.
30. Alexanian R, Dimopoulos M, Smith T et al. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512-516.
31. Fermand JP, Ravaud P, Chevret S et al. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell transplantation in multiple myeloma (MM): results of a prospective randomized trial (abstract). Blood 1996; 88 (Suppl. 1): 685a.
32. Einsele H, Bamberg M, Budach H et al. Total marrow irradiation, busulfan and cyclophosphamide followed by peripheral autologous PBSCT in patients with advanced multiple myeloma (abstract). Blood 1997; 90 (Suppl. 1): 112a.
33. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2793.